Coeptis Therapeutics (COEP) News Today → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Free COEP Stock Alerts $0.37 0.00 (0.00%) (As of 04/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineShort Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Grows By 171.3%americanbankingnews.com - April 11 at 1:03 AMComparing Coeptis Therapeutics (COEP) and Its Peersamericanbankingnews.com - April 9 at 1:56 AMCoeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Awardprnewswire.com - April 2 at 8:47 AMCOEP Stock Earnings: Coeptis Therapeutics Beats EPS for Q4 2023investorplace.com - April 1 at 11:03 AMCoeptis expands license for CAR technology to autoimmune diseasesinvesting.com - February 28 at 11:49 PMCoeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NKfinance.yahoo.com - February 26 at 9:12 AMCoeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NKprnewswire.com - February 26 at 9:00 AMCoeptis Therapeutics Holdings Inc Ordinary Shares COEPmorningstar.com - February 17 at 5:31 PMCoeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infectionsfinance.yahoo.com - February 7 at 10:18 AMCoeptis Therapeutics Risks Nasdaq Delisting Over Bid Pricemsn.com - February 2 at 10:19 AMThese are the 4 hottest stocks insiders bought in Januaryinsidertrades.com - January 29 at 2:00 PMCoeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024finance.yahoo.com - January 4 at 9:52 AMCoeptis Therapeutics Stock (NASDAQ:COEP) Insider Tradesbenzinga.com - December 9 at 7:09 PMCoeptis Therapeutics to Present at the Emerging Growth Conferencefinance.yahoo.com - December 4 at 10:31 AMBuy Rating for Coeptis Therapeutics Holdings Amidst Promising Cancer Cell Therapy Platforms and Exclusive Licensing Assetsmarkets.businessinsider.com - November 15 at 3:05 AMCoeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023finance.yahoo.com - October 31 at 10:19 AMCoeptis Therapeutics to raise $2M in a private placementmsn.com - October 24 at 10:45 AMCoeptis Therapeutics Announces $2 Million Private Placementfinance.yahoo.com - October 24 at 10:45 AMLocal pharma firm widens technology deal with the University of Pittsburghbizjournals.com - October 11 at 4:16 PMCoeptis Expands License Agreement With University Of Pittsburgh To Include SNAP-CAR Platformmarkets.businessinsider.com - October 11 at 11:15 AMCoeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapiesfinance.yahoo.com - October 9 at 10:31 AMCoeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meetingfinance.yahoo.com - October 4 at 7:57 AMCoeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesafinance.yahoo.com - September 27 at 12:15 PMSeattle biotech startup Deverra Therapeutics raising cash to develop cellular immunotherapiesmsn.com - September 20 at 1:29 AMCoeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infectionfinance.yahoo.com - September 14 at 9:36 AMCoeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowmentfinance.yahoo.com - September 11 at 9:00 AMCoeptis appoints Colleen Delaney as chief scientific and medical officerbizjournals.com - September 5 at 6:00 PMCoeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officerfinance.yahoo.com - August 30 at 5:34 PMCoeptics Flat on Deverra Dealbaystreet.ca - August 17 at 10:11 AMCoeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeuticsfinance.yahoo.com - August 17 at 10:11 AMCoeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnosticfinance.yahoo.com - August 1 at 3:24 PMAnalysts Are Bullish on These Healthcare Stocks: Mirati Therapeutics (MRTX), Clearside Biomedical (CLSD)markets.businessinsider.com - July 21 at 4:49 PMCoeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offeringfinance.yahoo.com - June 16 at 4:48 PMCoeptis Therapeutics Holdings, Inc. Announces Pricing Of $3.5M Underwritten Offeringbenzinga.com - June 14 at 10:15 AMCoeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offeringfinance.yahoo.com - June 14 at 10:15 AMEF Hutton Sticks to Its Buy Rating for Jasper Therapeutics (JSPR)markets.businessinsider.com - June 12 at 11:50 AMCoeptis Therapeutics to join Nasdaq Capital Market next Mondaybizjournals.com - June 9 at 4:50 PMCoeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Marketfinance.yahoo.com - June 9 at 11:50 AMCoeptis Therapeutics Shares Rally 67% In May, Clinical Interests And Planned Acquisitions Attract The Interest ($COEP)benzinga.com - May 30 at 7:46 AMCoeptis Therapeutics Appoints Brian Cogley as Chief Financial Officerfinance.yahoo.com - May 17 at 12:55 PMJonesTrading Keeps Their Buy Rating on Coeptis Therapeutics Holdings (COEP)markets.businessinsider.com - May 11 at 6:45 PMCoeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communicationsfinance.yahoo.com - May 10 at 4:40 PMJonesTrading Initiates Coverage of Coeptis Therapeutics Holdings (COEP) with Buy Recommendationmsn.com - April 19 at 7:44 PMBenzinga's Top Ratings Upgrades, Downgrades For April 19, 2023msn.com - April 19 at 2:44 PMCoeptis Rises on Key Assets Acquisition from Deverramsn.com - April 18 at 7:34 PMCoeptis Therapeutics to acquire cell therapies from Deverra Therapeuticsbizjournals.com - April 18 at 7:34 PMCoeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeuticsfinance.yahoo.com - April 18 at 9:12 AMAnalysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), Coeptis Therapeutics Holdings (COEP) and Day One Biopharmaceuticals (DAWN)markets.businessinsider.com - April 5 at 10:03 AMEF Hutton Reiterates Buy on Coeptis Therapeutics, Maintains $6 Price Targetbenzinga.com - March 31 at 6:59 PMShould You Hold Coeptis Therapeutics Holdings Inc (COEP) Stock Monday Morning?benzinga.com - March 29 at 11:16 PM Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Email Address Bitcoin Rockets To Record High But Buy THIS Instead (Ad)Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring… >>Click here to find out what it is. COEP Media Mentions By Week COEP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COEP News Sentiment▼-0.010.41▲Average Medical News Sentiment COEP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COEP Articles This Week▼00▲COEP Articles Average Week Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Inhibikase Therapeutics News SQZ Biotechnologies News Evaxion Biotech A/S News Senti Biosciences News Genetic Technologies News Organovo News BioCardia News BM Technologies News Sorrento Therapeutics News Creative Medical Technology News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COEP) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsUrgent alert: open this for a huge profit potentialTimothy SykesBiden out June 13; Kamala won’t replace him?Paradigm PressOptions trading has suddenly become more reliable.Eagle PublishingA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.